Nanostring Technologies has announced the first fixed-panel assay product to be developed on its Copy Number Variation (CNV) detection platform - the nCounter Human Karyotype Panel.
Researchers can use the nCounter Human Karyotype Panel with the nCounter Analysis System to accurately quantify chromosome number and detect aneuploidy - the existence of less than or more than the normal two chromosomes in a diploid genome that can play a role in cancer development and developmental disorders such as Down's Syndrome.
In addition to being a concern for human health, chromosomal aberrations occur during in vitro culture and are known to alter the biological properties of cells in culture and therefore compromise experimental results.
The assays are suitable for monitoring human-derived samples and cell lines for chromosomal abnormalities.
The Human Karyotype Panel provides precise, accurate and automated prediction of chromosomal copy number for all 24 human chromosomes in one reaction.
The nCounter Analysis System is a fully automated digital detection and counting system with a very simple workflow.
The assay kits contain all of the reagents and consumables required to conduct an experiment.
Minimal sample input requirements and compatibility with a variety of sample types extends the utility of the platform.
In addition to the human CNV assays, Nanostring provides assays for gene expression and miRNA analysis.
The nCounter Analysis System and Human Karyotype Panel are currently available for research use only.
